A. I. M. Hoepelman

727 total citations
21 papers, 349 citations indexed

About

A. I. M. Hoepelman is a scholar working on Epidemiology, Infectious Diseases and Hepatology. According to data from OpenAlex, A. I. M. Hoepelman has authored 21 papers receiving a total of 349 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Epidemiology, 9 papers in Infectious Diseases and 6 papers in Hepatology. Recurrent topics in A. I. M. Hoepelman's work include Hepatitis C virus research (6 papers), HIV/AIDS drug development and treatment (6 papers) and HIV Research and Treatment (5 papers). A. I. M. Hoepelman is often cited by papers focused on Hepatitis C virus research (6 papers), HIV/AIDS drug development and treatment (6 papers) and HIV Research and Treatment (5 papers). A. I. M. Hoepelman collaborates with scholars based in Netherlands, Germany and South Korea. A. I. M. Hoepelman's co-authors include Mathias Prokop, Eelko Hak, JW Lammers, Anke H. W. Bruns, Jan Jelrik Oosterheert, Monique Nijhuis, S.F.L. van Lelyveld, Hans Kieft, M. M. E. Schneider and Y. van der Graaf and has published in prestigious journals such as Clinical Infectious Diseases, Journal of Clinical Microbiology and The Journal of Infectious Diseases.

In The Last Decade

A. I. M. Hoepelman

21 papers receiving 336 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. I. M. Hoepelman Netherlands 12 172 108 64 61 49 21 349
Paola Tatarelli Italy 11 119 0.7× 145 1.3× 60 0.9× 21 0.3× 50 1.0× 23 303
Katherine McGowan United States 7 105 0.6× 90 0.8× 33 0.5× 33 0.5× 40 0.8× 15 312
Jesús Gaytán-Martı́nez Mexico 10 138 0.8× 124 1.1× 72 1.1× 25 0.4× 79 1.6× 33 395
Vincenzo Scaglione Italy 11 97 0.6× 111 1.0× 27 0.4× 29 0.5× 21 0.4× 40 353
Mario Cepparulo Italy 11 135 0.8× 53 0.5× 30 0.5× 56 0.9× 11 0.2× 22 373
Mas Chaponda United Kingdom 12 323 1.9× 156 1.4× 50 0.8× 101 1.7× 35 0.7× 21 554
Roberta Prinapori Italy 11 146 0.8× 215 2.0× 68 1.1× 15 0.2× 24 0.5× 24 311
Federica Tordato Italy 11 100 0.6× 186 1.7× 87 1.4× 13 0.2× 87 1.8× 20 339
Robin Dretler United States 9 202 1.2× 231 2.1× 107 1.7× 35 0.6× 30 0.6× 24 409
Catherine Knupp United States 7 170 1.0× 320 3.0× 232 3.6× 45 0.7× 54 1.1× 9 471

Countries citing papers authored by A. I. M. Hoepelman

Since Specialization
Citations

This map shows the geographic impact of A. I. M. Hoepelman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. I. M. Hoepelman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. I. M. Hoepelman more than expected).

Fields of papers citing papers by A. I. M. Hoepelman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. I. M. Hoepelman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. I. M. Hoepelman. The network helps show where A. I. M. Hoepelman may publish in the future.

Co-authorship network of co-authors of A. I. M. Hoepelman

This figure shows the co-authorship network connecting the top 25 collaborators of A. I. M. Hoepelman. A scholar is included among the top collaborators of A. I. M. Hoepelman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. I. M. Hoepelman. A. I. M. Hoepelman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Weehuizen, Jesper M., Annemarie M. J. Wensing, Tania Mudrikova, Ferdinand W N M Wit, & A. I. M. Hoepelman. (2019). Efficacy and safety of long-term maraviroc use in a heterogeneous group of HIV-infected patients: A retrospective cohort study. International Journal of Antimicrobial Agents. 54(2). 215–222. 8 indexed citations
2.
Veer, E. van der, et al.. (2017). Osteoporosis and osteopenia are not associated with T-cell activation in older cART-treated HIV-infected patients.. PubMed. 75(4). 138–144. 2 indexed citations
3.
Hoepelman, A. I. M., et al.. (2016). Greater carotid intima media thickness at a younger age in HIV‐infected patients compared with reference values for an uninfected cohort. HIV Medicine. 18(4). 275–283. 17 indexed citations
4.
Lelyveld, S.F.L. van, Jori Symons, Bridgette J. Connell, et al.. (2015). Clinical outcome of maraviroc-containing therapy in heavily pre-treated HIV-1-infected patients. International Journal of Antimicrobial Agents. 47(1). 84–90. 2 indexed citations
5.
Kievit, Wietske, Lubbertus C. Baak, C. M. Bakker, et al.. (2014). Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era.. PubMed. 72(8). 388–400. 13 indexed citations
6.
Kempen, Diederik H.R., M. van Dijk, A. I. M. Hoepelman, F. Cumhur Öner, & Jorrit‐Jan Verlaan. (2014). Extensive thoracolumbosacral vertebral osteomyelitis after Lemierre syndrome. European Spine Journal. 24(S4). 502–507. 7 indexed citations
7.
Boucher, Charles A., J.T. Brouwer, David M. Burger, et al.. (2013). Treatment of hepatitis C monoinfection in adults--Dutch national guidelines.. PubMed. 71(7). 377–85. 8 indexed citations
8.
Helsper, Charles W., Gerrit A. van Essen, G. Ardine de Wit, et al.. (2012). Real-life costs of hepatitis C treatment.. PubMed. 70(3). 145–53. 11 indexed citations
9.
Hermans, Lucas E., et al.. (2012). Delayed HIV testing in internal medicine clinics - a missed opportunity.. PubMed. 70(2). 69–73. 4 indexed citations
10.
Mudrikova, Tania, et al.. (2012). No increased risk of hepatotoxicity in long‐term use of nonnucleoside reverse transcriptase inhibitors in HIV‐infected patients. HIV Medicine. 13(7). 448–452. 9 indexed citations
11.
Arends, Joop E., et al.. (2011). Low doses of the novel caspase-inhibitor GS-9450 leads to lower caspase-3 and -8 expression on peripheral CD4+ and CD8+ T-cells. APOPTOSIS. 16(9). 959–966. 11 indexed citations
12.
Symons, Jori, S.F.L. van Lelyveld, A. I. M. Hoepelman, et al.. (2011). Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient. Journal of Antimicrobial Chemotherapy. 66(4). 890–895. 24 indexed citations
13.
Manns, M.P., Eric Lawitz, A. I. M. Hoepelman, et al.. (2010). 273 SHORT TERM SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ACTIVITY OF GS-9450, A SELECTIVE CASPASE INHIBITOR, IN PATIENTS WITH CHRONIC HCV INFECTION. Journal of Hepatology. 52. S114–S115. 10 indexed citations
14.
Lelyveld, S.F.L. van, Monique Nijhuis, Ingeborg Wilting, et al.. (2010). Therapy Failure following Selection of Enfuvirtide‐Resistant HIV‐1 in Cerebrospinal Fluid. Clinical Infectious Diseases. 50(3). 387–390. 26 indexed citations
15.
Bruns, Anke H. W., Jan Jelrik Oosterheert, Mathias Prokop, et al.. (2007). Patterns of Resolution of Chest Radiograph Abnormalities in Adults Hospitalized with Severe Community-Acquired Pneumonia. Clinical Infectious Diseases. 45(8). 983–991. 54 indexed citations
16.
Lobatto, S., et al.. (1999). A randomised, multicentre study of ceftriaxone versus standard therapy in the treatment of lower respiratory tract infections. International Journal of Antimicrobial Agents. 12(2). 121–127. 12 indexed citations
17.
Lohuis, Peter J. F. M., et al.. (1997). Leishmania braziliensis presenting as a granulomatous lesion of the nasal septum mucosa. The Journal of Laryngology & Otology. 111(10). 973–975. 13 indexed citations
18.
Schneider, M. M. E., et al.. (1995). Efficacy and Toxicity of Two Doses of Trimethoprim-Sulfamethoxazole as Primary Prophylaxis against Pneumocystis carinii Pneumonia in Patients with Human Immunodeficiency Virus. The Journal of Infectious Diseases. 171(6). 1632–1636. 50 indexed citations
19.
Kieft, Hans, et al.. (1994). Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome. Antimicrobial Agents and Chemotherapy. 38(3). 415–421. 25 indexed citations
20.
Hoepelman, A. I. M., Hans Kieft, Mabel Aoun, et al.. (1993). International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections. Journal of Antimicrobial Chemotherapy. 32(suppl B). 175–186. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paola Tatarelli Breakdown of academic impact, for papers by Katherine McGowan Breakdown of academic impact, for papers by Jesús Gaytán-Martı́nez Breakdown of academic impact, for papers by Vincenzo Scaglione Breakdown of academic impact, for papers by Mario Cepparulo Breakdown of academic impact, for papers by Mas Chaponda Breakdown of academic impact, for papers by Roberta Prinapori Breakdown of academic impact, for papers by Federica Tordato Breakdown of academic impact, for papers by Robin Dretler Breakdown of academic impact, for papers by Catherine Knupp
Rankless by CCL
2026